HCTI
Healthcare Triangle, Inc.
There isn't enough reported data to score HCTI yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HCTI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Unavailable | |
| Unavailable |
HCTI's revenue is currently strong, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCTI PE Valuation
HCTI has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HCTI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect HCTI's losses to grow, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HCTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$262,944.00 | +$19,558.66 |
| Q4 2024 | -$337,644.00 | +$48,323.57 |
HCTI lost $262,944.00 per share over the past year, about the same as its loss the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HCTI in the latest year-over-year earnings comparison.
HCTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $9.2M | +158% |
| Q1 2026 | $9.9M | +166% |
| Q4 2025 | $3.1M | +43% |
| Q3 2025 | $3.5M | +45% |
| Q2 2025 | $3.6M | +19% |
| Q1 2025 | $3.7M | -9.9% |
| Q4 2024 | $2.2M | -69% |
| Q3 2024 | $2.4M | -69% |
HCTI's revenue is recovering but still below its 2022 peak: $9M last quarter, up 158% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -44% | -6.1 points |
| Q1 2026 | -37% | +1 points |
| Q4 2025 | -142% | -119 points |
| Q3 2025 | -74% | -26 points |
| Q2 2025 | -38% | +8 points |
| Q1 2025 | -38% | +3.8 points |
| Q4 2024 | -23% | -3.4 points |
| Q3 2024 | -48% | -29 points |
HCTI's operating margin was −44% last quarter, down 6.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HCTI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HCTI on profitability, with a higher operating margin.
HCTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.9M | -$1.3M |
| Q4 2023 | $594K | +$2.8M |
| Q2 2023 | -$1.2M | -507% |
| Q1 2023 | -$1.6M | -631% |
| Q4 2022 | -$2.2M | +$1.2M |
HCTI has burned cash in most quarters: −$21M over the past year, against −$4M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HCTI in the latest year-over-year cash flow comparison.
HCTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +201% | +93.7K shares |
| 1 year | +779217% | +140K shares |
HCTI has 140,277 diluted shares, up 779217% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | $51,000 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HCTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HCTI Net Leverage
HCTI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HCTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 0.2 | Oversold |
HCTI's weekly RSI is 33 (neutral) and its Stochastic is 0 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HCTI PE vs Healthcare Sector
HCTI has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HCTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.37 | 55% below |
| 20 week MA | $18.1 | 79% below |
| 50 week MA | $269.1 | 99% below |
| 100 week MA | $34,100.7 | 100% below |
| 200 week MA | $360,400.1 | 100% below |
HCTI is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HCTI on trend strength, trading above more of its moving averages.
HCTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10,338,480.0 | $5,378,400.0 | -48% |
| 2022 | $5,378,400.0 | $624,492.0 | -88% |
| 2023 | $624,492.0 | $815,724.0 | +31% |
| 2024 | $815,724.0 | $237,130.7 | -71% |
| 2025 | $237,130.7 | $1,380.0 | -99% |
| 2026 YTD | $1,380.0 | $3.74 | -100% |
HCTI has finished lower in four of the last five years. It's down 100% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HCTI on returns for 2026, with the stronger performance.